This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
The authors designed a randomised controlled trial based at multiple centres across the UK. The patients were randomised to the treatment groups in a ratio of 1:1:1:1:1. Randomisation was carried out by the clinician telephoning a central randomisation service and providing patient identifying information. The centre, gender, and treatment history (newly diagnosed and untreated, treated with ineffective monotherapy, relapse after remission) were used to stratify patients. A minimisation procedure was then used to allocate the patients to the groups. Blinding was not carried out. The patients were followed up at 3 months, 6 months and 1 year, and at successive yearly intervals for up to 6 years. Oxcarbazepine was added to the study only after the trial had been running for some time. Therefore, analyses were carried out both with and without this drug.
Analysis of effectiveness
Analysis was carried out on an intention to treat basis, supplemented by per-protocol calculations. The primary outcomes were: the time from randomisation to treatment failure (stopping the randomised drug because of inadequate seizure control and/or intolerable side-effects; or the addition of other antiepileptic drugs), and the time from randomisation to a 1-year period of remission of seizures.
Extensive clinical and demographic data were collected at baseline. A comparison of the groups revealed that they were "well balanced"; there were no reported statistically significant differences. A further 39 patients were lost to follow-up during the study, 38 because they declined further follow-up and one patient who had left the country. Time-to-event data were reported to have used cumulative incidence analysis and Cox proportional hazard models; cumulative incidence was used as log rank tests were not considered appropriate. The authors reported that follow-up was 94% complete.
Effectiveness results
Numerous results were presented in the paper, of which a small selection of relevant results has been presented in this abstract.
For time to treatment failure, there were significant differences between drugs when comparisons were made over the whole period. Lamotrigine was reported as being "better than all other drugs for pairwise comparisons", carbamazepine and oxcarbazepine were intermediate, and gabapentin and topiramate were the poorest performing drugs.
The sensitivity analysis revealed that including only patients with definite partial seizures, or including patients subsequently withdrawn as "not epilepsy", did not affect the results.
The hazard ratio for treatment failure due to unacceptable events was 0.62 (0.46 to 0.83) between lamotrigine and carbamazepine, 0.62 (0.46 to 0.84) between lamotrigine and topiramate, and 0.6 (0.44 to 0.81) between gabapentin and carbamazepine.
Carbamazepine was most likely to be associated with treatment failure due to unacceptable adverse events.
Gabapentin was most likely to be associated with treatment failure due to inadequate seizure control and carbamazepine the least likely. The hazard ratio between gabapentin and carbamazepine was 2.45 (1.81 to 3.32).
The intention to treat analysis revealed statistical differences for 12-month remission, with gabapentin and topiramate the least favoured options and carbamazepine the most preferred treatment.
There was no evidence that relative treatment effects differed across age groups. The authors concluded that "for patients with partial onset seizures that need monotherapy, we have found lamotrigine to be significantly better for time to treatment failure than the current standard treatment, carbamazepine".
Clinical conclusions

Measure of benefits used in the economic analysis
The authors used quality of life measured by "a battery of previously validated generic and epilepsy-specific measures" as a summary measure of health benefit. For adults, the Newly Diagnosed Epilepsy Quality of Life (NEWQOL) questionnaire was used. EQ-5D responses were used to measure quality-adjusted life-years (QALYs). The final analysis was based on 1,009 adult patients who provided complete EQ-5D responses at 2 years. The authors reported that details of the methods used in assessing quality of life outcomes were given online (web appendix, web figure 1, web tables 2 and 3. The number of seizures avoided was also used as a summary measure of health benefit.
Direct costs
Few details of the cost-effectiveness analysis were given in the current report. The authors stated that further details are available online. The perspective of the analysis was not reported. The analysis focused on the patients' use of resources and classified use as either consumption of antiepileptic drugs, resource use associated with the management of adverse events needing hospitalisation, and use of other health care and social services resources. A table giving details of disaggregated costs was reported to be available online.
Statistical analysis of costs
A statistical analysis of the costs and quantities was not reported to have been carried out.
Indirect Costs
Productivity costs were not reported to have been estimated.
Currency
UK pounds sterling ().
Sensitivity analysis
Bootstrapping was used to generate cost-effectiveness acceptability curves. The number of repetitions used was not stated. The authors also used high and low cost estimates, but these were not fully explained or reported. Further details of the methods underlying this analysis were reported to be available online.
Estimated benefits used in the economic analysis
Results excluding oxcarbazepine: 
Cost results
The costs were difficult to interpret from the paper. 
Synthesis of costs and benefits
In all analyses topiramate and gabapentin were either dominated or least preferred by extended dominance (more costly with fewer associated outcomes).
With analyses including oxcarbazepine, lamotrigine was either dominated or not preferred because of principles of extended dominance.
With analyses excluding oxcarbazepine, the incremental cost for lamotrigine was 11,851 per QALY gained, or 80 per seizure avoided.
The incremental cost for oxcarbazepine was 6,200 per QALY gained, or 35 per seizure avoided.
